Skip to main content

Table 1 Baseline characteristics for males and females of the low dose group (IGF-1 target level between − 2 and − 1 SDS) and the high dose group (IGF-1 target level between 1 and 2 SDS)

From: Effect of low-normal and high-normal IGF-1 levels on memory and wellbeing during growth hormone replacement therapy: a randomized clinical trial in adult growth hormone deficiency

  Males Females
Low Dose
n = 10
High Dose
n = 11
Low Dose
n = 6
High Dose
n = 5
Age (years) 46.3 (11.2) 47.4 (8.9) 49.1 (10.7) 44.3 (10.9)
CO GH deficiency (%) 80 27* 33 0
Duration GH treatment (years) 18.6 (9.4) 13.4 (6.3) 8.9 (5.3) 4.8 (1.8)
IGF-1 in SDS 0.29 (0.62) −0.38 (0.38)** −0.08 (0.57) − 0.03 (0.42)
BMI (kg/m2) 25.6 (3.4) 28.6 (3.8) 33 (14.5) 29 (5.2)
Cranial radiotherapy (%) 10 18 0 0
Pituitary surgery (%) 10 54 17 40
Isolated GH deficiency (%) 20 26 33 0
LH/FSH deficiency (%) 80 45 33 40
TSH deficiency (%) 70 64 17 80
ACTH deficiency (%) 80 64 33 60
ADH deficiency (%) 0 36 0 0
Diabetes mellitus (%) 10 0 33 0
CVD (%) 0 18 50 40
Married (%) 60 73 83 60
Education 10–13 years (%) 30 18 16 40
Education > 13 years (%) 70 82 83 60
  1. Values are mean (SD) unless stated otherwise
  2. CO childhood onset GH deficiency, GH growth hormone, IGF-1 in SDS insulin like growth factor-1 in standard deviation score, BMI body mass index, LH/FSH luteinising hormone/follicle stimulating hormone, TSH thyroid stimulating hormone, ACTH adrenocorticotropic hormone, ADH antidiuretic hormone, CVD cardiovascular disease
  3. *p < 0.05, ** p < 0.01 (low dose versus high dose)